# Defining the resistome in P. falciparum: evolution and mechanism

> **NIH NIH R01** · UNIVERSITY OF CALIFORNIA, SAN DIEGO · 2023 · $1,083,911

## Abstract

SUMMARY
Although improvements have been made to the antimalarial drug discovery pipeline over the past decade a
substantial risk remains that many new drug candidates may fail in clinical trials due to the rapid emergence of
drug resistant parasites. The longterm goal of this research is to design better preclinical drug candidates for
both malaria and to understand why treatments may fail. Over the past decade, our investigative team has
established robust methodologies for discovering and characterizing genes involved in multidrug resistance and
has assembled a large dataset of genes and alleles that mediate or are associated with multidrug resistance.
The overall objective of this application is to extend and leverage these data to determine when, how and why
antimalarial drug resistance or persistence emerges. Our central hypothesis is that the emergence of clinical
drug resistance can be predicted using in vitro evolution assays. We also posit that resistance parameters may
differ substantially between current field isolates exposed to modern first-line drugs and other selective
pressures, as compared with reference laboratory strains isolated decades ago. Our hypotheses will be tested
by pursuing three specific aims. In Aim 1, we will use adaptive laboratory evolution and deep whole-genome
sequencing to obtain a high-resolution view of drug resistance acquisition. To accomplish this, we will define the
extent to which a parasite’s genetic background plays a role by comparing results from recent African, Asian and
South American clinical isolates to those obtained with laboratory strains dating back >40 years. We will also
test whether these strains differ fundamentally in their mutational paths, levels of and time to resistance, the
minimum inoculum of resistance and the impact of resistance on parasite fitness. We will also answer the critical
question of whether resistance liabilities are more a function of the target or of the chemotype, parameters that
contribute to resistance emergence such as number of genome replication events and the number of different
alleles and whether different chemical chemotypes interacting with a given drug target give different results. In
Aim 2, we will seek to understand mechanisms of resistance in a panel of poorly understood mediators. These
studies will combine conditionally regulated genetic, proteomic, cellular and structural approaches to studying
the impact of genetic changes conferring resistance on parasite biology. In Aim 3, we will explore the role that
P. falciparum genes play in mediating drug tolerance as a means to survive antiplasmodial pressure. Innovation
includes characterizing the evolution of resistance in geographically distinct modern field isolates instead of
relying entirely on historical laboratory strains. Novelty includes assessing whether the resistance risk is driven
by the target or the chemotype,and defining the role for tolerance in surviving antimalarial exposure. This
re...

## Key facts

- **NIH application ID:** 10608899
- **Project number:** 1R01AI169892-01A1
- **Recipient organization:** UNIVERSITY OF CALIFORNIA, SAN DIEGO
- **Principal Investigator:** Daniel E. Goldberg
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2023
- **Award amount:** $1,083,911
- **Award type:** 1
- **Project period:** 2022-11-02 → 2027-10-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10608899

## Citation

> US National Institutes of Health, RePORTER application 10608899, Defining the resistome in P. falciparum: evolution and mechanism (1R01AI169892-01A1). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10608899. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*